Gland Pharma Ltd Stock Price Today (NSE: GLAND)
Fundamental Score
Gland Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gland Pharma Ltd share price today is ₹2197.60, up +0.87% on NSE/BSE as of 17 June 2026. Gland Pharma Ltd (GLAND) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹28.46K (Cr). The 52-week high for GLAND share price is ₹2396.00 and the 52-week low is ₹1573.60. At a P/E ratio of 36.01x, GLAND is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 7.81% and a debt-to-equity ratio of 0.03.
Gland Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Gland Pharma Ltd share price chart: 30.27% return over the past month. 52-week high ₹2396.00, 52-week low ₹1573.60.
Gland Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2268.90 | ₹2337.50 | ₹2263.20 | ₹2277.00 | 4.82L (Cr) | |
| ₹2278.60 | ₹2356.50 | ₹2255.80 | ₹2292.40 | 5.85L (Cr) | |
| ₹2315.00 | ₹2337.50 | ₹2230.00 | ₹2250.00 | 2.19L (Cr) | |
| ₹2313.00 | ₹2313.00 | ₹2313.00 | ₹2313.00 | 0.00 (Cr) | |
| ₹2324.10 | ₹2354.70 | ₹2309.20 | ₹2313.00 | 2.24L (Cr) | |
| ₹2339.70 | ₹2354.70 | ₹2252.10 | ₹2307.90 | 8.74L (Cr) | |
| ₹2369.80 | ₹2396.00 | ₹2321.10 | ₹2333.80 | 5.06L (Cr) | |
| ₹2353.50 | ₹2363.50 | ₹2307.20 | ₹2334.00 | 8.64L (Cr) | |
| ₹2230.00 | ₹2370.00 | ₹2230.00 | ₹2331.00 | 10.19L (Cr) | |
| ₹2232.90 | ₹2295.10 | ₹2201.90 | ₹2221.80 | 11.80L (Cr) |
Gland Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2278.60 | ₹2356.50 | ₹2255.80 | ₹2277.00 | -0.07% | |
| ₹1750.80 | ₹2396.00 | ₹1748.00 | ₹2250.00 | +28.51% | |
| ₹1701.70 | ₹1832.00 | ₹1652.00 | ₹1750.80 | +2.89% | |
| ₹1780.00 | ₹1802.10 | ₹1573.60 | ₹1696.10 | -4.71% | |
| ₹1815.80 | ₹1984.90 | ₹1748.90 | ₹1822.20 | +0.35% | |
| ₹1716.60 | ₹1874.80 | ₹1650.00 | ₹1846.60 | +7.57% | |
| ₹1768.20 | ₹1815.00 | ₹1629.60 | ₹1722.00 | -2.61% | |
| ₹1942.70 | ₹2034.00 | ₹1730.00 | ₹1759.60 | -9.43% | |
| ₹1992.00 | ₹2026.10 | ₹1889.00 | ₹1928.90 | -3.17% | |
| ₹1880.00 | ₹2074.00 | ₹1848.10 | ₹1991.60 | +5.94% | |
| ₹2060.00 | ₹2089.40 | ₹1852.60 | ₹1871.50 | -9.15% | |
| ₹1842.30 | ₹2131.00 | ₹1822.40 | ₹2064.80 | +12.08% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Expensive injectables pure-play; execution is everything.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Gland Pharma appointed Mr. Prasadha Rao Lysetti as Sr. Vice-President (Head - Operations). The company also scheduled an analyst meeting with Ventura Securities for March 23, 2026. Gland Pharma disclosed receiving a GST tax demand order of for FY2019-20, but believes there will be no material impact.
CORE STORY (THE REAL GAME)
- Strong Q3FY26 results
- Cenexi turnaround
- Increased R&D investments
- New complex generic approvals
- Large CDMO contract wins
- Fosun stake sale resolution
- US generics pricing pressure
- Fosun stake sale overhang
- Quality control issues
FII increased stake by 0.51% while DII decreased stake by 0.23%
Indian pharma exports growing at 5.6%, targeting $65 billion by 2030
New CMO contract signed for a complex Nano Drug Delivery System in Oncology
Yes; Free Cash Flow 5Y: ₹1906.83 Cr
Expect stronger momentum driven by new launches and Cenexi's recovery. Investments in CDMO expansion and complex injectables pipeline continue to strengthen foundation.
Primary Thesis Risk
US generics pricing pressure could erode margins.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Gland Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gland Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLAND across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (28.28%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (16.36% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (24.88x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1906.83 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.83%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 40.53%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (7.81%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Weak Earnings Growth (-2.89% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-1.69% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Gland Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Gland Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Gland Pharma LtdGland Pharma Lt...Selected✓ GLAND • 543245 | 45.5/100 | ₹2197.60₹2198 | ₹28463.26₹28463.26 | 36.01Average 36.0 Average | 7.81%Poor 7.81% Poor | 11.89%Average 11.89% Average | 0.03Excellent 0.0 Excellent | -1.69%Poor -1.69% Poor | 16.36%Excellent 16.36% Excellent | 1.04% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Gland Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for GLAND — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹42.40 | ₹1722.00 | 40.6x |
| FY 2024 | ₹46.89 | ₹1779.35 | 37.9x |
| FY 2023 | ₹47.43 | ₹1924.50 | 40.6x |
| FY 2022 | ₹73.64 | ₹1576.55 | 21.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Gland Pharma Ltd Dividend History
Annual cash dividends paid by GLAND — dividend yield 1.04%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹329.49 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Gland Pharma Ltd Quarterly Performance
Latest quarterly metrics for GLAND — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
5.77%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
12.32%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.36%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-1.69%
Compounded annual net profit growth over 5 years
Gland Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GLAND — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Gland Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Gland Pharma Ltd (GLAND) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Gland Pharma Ltd
About GLAND (Gland Pharma Ltd)
Gland Pharma Ltd is a global pharmaceutical powerhouse specializing in sterile injectables, a critical and complex field requiring precision and expertise. They develop, manufactur...e, and market a diverse range of injectable products, catering to various therapeutic areas and dosage forms. The company distinguishes itself through its commitment to quality and regulatory compliance, adhering to stringent international standards across its facilities. From vials and ampoules to pre-filled syringes and lyophilized products, Gland Pharma offers a comprehensive portfolio to meet the evolving needs of healthcare providers and patients worldwide. Their expansive geographical reach ensures that vital medications are accessible to communities across the globe, solidifying their position as a trusted provider of essential injectable pharmaceuticals. Beyond its manufacturing capabilities, Gland Pharma also invests significantly in research and development, with a focus on developing innovative injectable formulations and enhancing existing products. They are actively involved in the development of complex molecules, including peptides and biosimilars, signaling a forward-thinking approach to address unmet medical needs. This commitment to innovation extends to exploring novel drug delivery systems and formulations that improve patient outcomes and reduce healthcare costs. By combining its robust manufacturing infrastructure with a dynamic R&D pipeline, Gland Pharma is strategically positioned to capitalize on emerging opportunities in the global injectable market and maintain its competitive edge in the long term. This positions them as more than just a manufacturer, but an innovator in the space. Gland Pharma’s success is underpinned by a strong foundation of technical expertise, quality control systems, and a customer-centric approach. The company fosters a culture of continuous improvement, constantly seeking ways to optimize its processes and enhance the value it delivers to its partners. Their commitment to sustainability is evident in their environmentally conscious manufacturing practices and responsible sourcing of raw materials. This dedication to ethical and sustainable practices aligns with the growing demand for responsible corporate citizenship within the pharmaceutical industry. Ultimately, Gland Pharma strives to be a reliable and trusted partner, delivering high-quality injectable medications that improve the lives of patients around the world.
Company Details
Key Leadership
Corporate Events
GLAND Share Price: Frequently Asked Questions
What is the current share price of Gland Pharma Ltd?
Gland Pharma Ltd (GLAND) trades at ₹2197.60 on NSE and BSE. Market cap ₹28.46K (Cr). Educational data only.
What is the P/E ratio of Gland Pharma Ltd?
Gland Pharma Ltd has a P/E of 36.01x vs industry average 31.77x.
What is the Bull Run score for Gland Pharma Ltd?
Gland Pharma Ltd has a Bull Run score of 45.5/100 based on 25+ financial parameters.
Does Gland Pharma Ltd pay dividends?
Gland Pharma Ltd has a dividend yield of 1.04%. Past dividends don't guarantee future payments.
What is the ROE of Gland Pharma Ltd?
Gland Pharma Ltd has ROE of 7.81%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Gland Pharma Ltd?
Gland Pharma Ltd has debt-to-equity of 0.03.
Is Gland Pharma Ltd a good investment?
Bull Run gives Gland Pharma Ltd a score of 45.5/100. This is not investment advice — consult a SEBI-registered advisor.